New Solution for Pain: LumaCina's Oral Morphine Now Available in New Zealand

Introduction to the Oral Morphine Shortage

New Zealand has been grappling with a significant shortage of Oral Morphine, a critical medication used for pain management. Patients who require this drug for chronic or severe pain relief have been facing difficulties in accessing it, leading to detrimental impacts on their quality of life.

LumaCina’s Response to the Crisis

Seeing the urgent need to address this issue, LumaCina, a pharmaceutical company based in Australia, has announced that they are ramping up production of Oral Morphine. This move is in collaboration with Pharmac, the New Zealand government agency responsible for ensuring the availability of necessary medicines.

LumaCina has significantly invested in increasing its production capabilities. This effort aims to ensure a steady supply of Oral Morphine, thereby alleviating the prevalent shortage and helping patients manage their pain more effectively.

The Importance of Collaboration

Both LumaCina and Pharmac are employing their collective expertise and resources to address the situation. This partnership underscores the importance of international collaboration in resolving pharmaceutical shortages. By pooling their strengths, these organizations are making strides towards improving the healthcare landscape in New Zealand.

Statements from Key Figures

Cyrus K. Mirsaidi, Global CEO of LumaCina and Bridgewest Perth Pharma, has emphasized the company’s commitment to ensuring that patients get the pain relief they need. He noted that LumaCina’s investment and efforts are focused on enhancing the quality of life for those affected by the shortage.

Dr. Masood Tayebi, CEO and Founding Partner of Bridgewest Group, echoed these sentiments. He highlighted the broader vision of making a positive impact on public health through strategic investments and expansion in the life sciences sector.

Expansion of Capabilities

Last year, Bridgewest Group undertook significant measures to expand its capabilities in the life sciences domain. This included acquiring the Pfizer Perth cGMP sterile injectable manufacturing plant. The formation of Bridgewest Perth Pharma, NovaCina CDMO division, and LumaCina pharmaceutical supply division are crucial steps in this expansion.

These strategic moves are intended to enhance the group’s research, development, manufacturing, and delivery capabilities, ensuring that high-quality medications are accessible to the patients who need them the most.

About LumaCina

LumaCina is a global supplier and marketer of sterile injectable pharmaceutical drugs, headquartered in Perth, Australia. The company is focused on expanding its infrastructure and industry partnerships to develop a comprehensive pipeline of high-quality medications, including high potency drugs, multi-format vials, and more.

As a part of the Bridgewest Group Portfolio, LumaCina is dedicated to addressing critical medical needs and improving patient outcomes through innovative solutions and strategic partnerships.

Looking Ahead

The prompt response by LumaCina and their collaboration with New Zealand’s Pharmac showcases their dedication to addressing pharmaceutical shortages. This initiative not only promises to resolve the current Oral Morphine shortage but also sets a precedent for future responses to similar crises.

As efforts continue, the collaboration between LumaCina and Pharmac paves the way for sustained improvements in the availability of critical medications, benefitting countless patients who depend on these drugs for effective pain management.

Conclusion

The increased production and availability of Oral Morphine by LumaCina is a significant development for New Zealand’s healthcare system. This collaborative effort between LumaCina and Pharmac represents a proactive approach to solving critical drug shortages and ensuring patients have access to necessary pain relief medications.

With ongoing investments and strategic partnerships, LumaCina is well-positioned to make a lasting impact on public health and continue delivering high-quality pharmaceutical solutions.